Pharmacogenomics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

The Pharmacogenomics Market size is estimated at USD 10.27 billion in 2025, and is expected to reach USD 15.61 billion by 2030, at a CAGR of 8.73% during the forecast period (2025-2030).

Clinical adoption is expanding as health systems weave pre-emptive genetic testing into routine workflows, trimming trial-and-error prescribing and lowering adverse reactions. Medicare's 2024 Local Coverage Determinations and the FDA's companion-diagnostic guidance have created clearer reimbursement and regulatory pathways, encouraging laboratories to scale capacity. Demand accelerates in pain management, where CYP2D6 testing supports opioid stewardship and posts the fastest segment CAGR of 13.75%. Asia-Pacific shows double-digit growth as China and India embed pharmacogenomic programs in national health strategies. Meanwhile, AI-driven software platforms shorten interpretation time and increasingly steer buying decisions for hospitals.

Global Pharmacogenomics Market Trends and Insights

Rising Demand for Personalized Medicine

Health systems now view genetic testing as core infrastructure because outcome data show 42% fewer prescribing adjustments and higher adherence when pre-emptive panels are used. The PREPARE multisite study reported a 33% drop in drug-related adverse events under pharmacogenomic guidance. Veterans Affairs has rolled out a nationwide program to align drug choice with veterans' genotypes, moving away from one-size-fits-all prescribing. These benefits underpin steady pharmacogenomics market growth even in budget-constrained systems. Data-rich implementation models also help payers quantify long-term savings, strengthening coverage proposals.

Advancements in Genetic Sequencing Technologies

Illumina's NovaSeq X has lowered per-sample costs while boosting throughput, making comprehensive panels affordable for community hospitals. Oxford Nanopore and PacBio long-read platforms now resolve CYP2D6 structural variants missed by earlier methods. A University of Illinois nanopore system compresses sequencing time from 2 weeks to 1 hour, cutting costs by 90% and enabling near-patient testing. Third-generation tools capture complex haplotypes in under-represented populations, closing equity gaps and expanding the addressable pharmacogenomics market. Faster, cheaper sequencing also frees budgets for informatics and counseling services.

High Costs Associated with Pharmacogenomic Testing

Comprehensive panels range from USD 200-2,000, creating affordability gaps for uninsured patients and small clinics. Rural providers also shoulder training and IT integration expenses, delaying roll-outs. Upfront investment in decision-support engines strains capital budgets, although modeling shows long-run savings from fewer adverse reactions. Bulk-purchasing consortia and machine-learning triage tools help curb per-test charges. Cost declines in reagents and sequencing hardware are expected to ease this restraint in the medium term.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Prevalence of Chronic and Genetic Diseases
2. Increasing Research and Development Investments
3. Limited Reimbursement Coverage

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Reagents and kits represented 44.34% of pharmacogenomics market share in 2024, underpinned by high test volumes and consumable pull-through. Yet software and services are expanding fastest at 11.01% CAGR, reflecting a pivot toward actionable insights over raw sequence data. Hospitals favor AI-assisted decision-support modules that plug directly into electronic health records, reducing interpretation time from hours to minutes. PGxAI's Deneb model exemplifies this shift by blending pharmacogenetic calls with drug-response algorithms to inform dosing adjustments. Instruments remain a steady contributor as vendors integrate sample prep, amplification and analytics into single bencheside units, easing workflow complexity.

The convergence of wet-lab and digital components is redefining solution bundles within the pharmacogenomics market. QIAGEN's QIAcuity digital PCR line added 100 assays in 2024 to support oncology, cardiology and pain panels. Service contracts now include tele-genetic counseling to meet accreditation standards for informed consent. As cloud infrastructure matures, subscription-based bioinformatics is displacing perpetual licenses, smoothing cash flow for both suppliers and clinics. These trends reinforce the pharmacogenomics market size trajectory by shifting revenue toward recurring analytics and support offerings.

DNA sequencing already commands 32.66% of pharmacogenomics market share and is projected to grow at 12.12% CAGR, lifted by falling reagent costs and richer variant detection. Illumina's NovaSeq X platform reduced per-genome costs, unlocking population-scale screening for large health networks. Long-read instruments from PacBio map complex CYP2D6 rearrangements critical for opioid dosing.

Microarrays remain relevant for high-throughput targeted panels, especially the Infinium Global Diversity Array with 1.9 million PGx markers. PCR assays win where rapid turnaround is vital, such as perioperative antiplatelet management. Mass-spectrometry and electrophoresis retain niche roles. The net effect is continued consolidation around multi-omics sequencing hubs, strengthening the pharmacogenomics market.

The Pharmacogenomics Market is Segmented by Product & Service (Instruments, Reagents & Kits, and More), Technology (Polymerase Chain Reaction, DNA Sequencing, and More), Sample Type (Blood, and More), Application (Drug Discovery & Development, Oncology, Neurology, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America accounted for 41.91% of the pharmacogenomics market in 2024, underpinned by mature lab infrastructure, CPIC implementation resources and supportive FDA frameworks. Mayo Clinic and University of Colorado provide blueprints for workflow integration, while the Veterans Affairs program extends reach across 9 million enrollees. Nonetheless, payer variability persists, with UnitedHealthcare's 2024 coverage curbs dampening multigene panel uptake myriad.com.

Europe shows steady advances as the European Medicines Agency finalized AI-driven pharmacogenomic guidance in 2024, giving manufacturers clarity to scale companion-diagnostic submissions. National health services in France, Germany and the Nordics are piloting population panels to measure long-term cost offsets, promoting broader pharmacogenomics market penetration.

Asia-Pacific is the fastest-growing region, forecast at 14.75% CAGR. China's Five-Year Health Plan embeds pharmacogenomic screening into public hospitals and secures domestic sequencing supply chains. Indian start-ups like Acrannolife provide locally priced PGx bundles for cardiology and psychiatry. Singapore research found 46.1% of participants carried actionable CYP2D6 alleles, underscoring unmet need nature.com. Expansive population cohorts and diverse haplotypes augment global biomarker discovery pipelines, amplifying the overall pharmacogenomics market size.

1. Abbott Laboratories
2. Agilent Technologies
3. Beckton Dickinson
4. bioMerieux
5. Bio-Rad Laboratories
6. Eurofins
7. Roche
8. Illumina
9. Merck
10. Pacific Biosciences
11. PerkinElmer
12. QIAGEN
13. Thermo Fisher Scientific
14. Myriad Genetics
15. Genomind
16. OneOme
17. Admera Health
18. Genelex
19. Coriell Life Sciences
20. Danaher
21. Luminex
22. Color Health
23. Natera

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support